Contents: Market Access 2021

Introduction

Welcome from the Editor

Click here

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients

Click here

“A long way to go” for digital health reimbursement

A recent analysis delves into the challenges digital health technologies face in getting reimbursed and asks how they can find a smoother path to market

Click here

The pharma world at your fingertips
The pharma world at your fingertips

Daily News from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Time for a NICE change

Leela Barham takes stock of the NICE Methods Review and what it could mean for the industry

Click here

How will NICE fare in a post-Brexit world?

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage

Click here

AI meets RWE: The future of drug assessment?

Savana’s Dr Ignacio Medrano explains how natural language processing is opening up huge amounts of previously-inaccessible real-world evidence for pharma and regulators

Click here

Research predicts the post-COVID landscape for HCP engagement

Liz Murray takes us through IQVIA’s latest research into HCPs’ attitudes to pharma engagement, and asks how sales forces can adapt for future changes

Click here

A year on: pandemic driven trends in HCP Engagement

IQVIA’s John Procter explores why the industry should be paying attention to the changing customer experience in the wake of COVID-19.

Click here

How the patient voice is becoming vital for drug approval

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease

Click here

Putting patients at the centre of medicine reimbursement

Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this.

Click here

Podcast

Listen to discussions of key industry trends with leading pharma figures

Click here

Rethinking access barriers to innovation

Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages.

Click here

How to improve payer engagement with tailored value communication

Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing and commercial strategy could be the key to significantly improving pharma’s payer engagement.

Click here

Building honest dialogue with patient advocates

How can the industry listen to patients in a way that puts the person behind the disease first? Blogger Chris Aldred and Joe Delahunty from Ascensia discuss what the industry often gets wrong in its patient engagement

Click here

PTC Therapeutics’ Alberto Vicent on listening to the ultra-rare disease communities
Listening to the ultra-rare disease communities

When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. Alberto Vicent from PTC Therapeutics explains why we need to view ultra-rare populations differently, so they can also access treatments

Click here

Forthcoming issues of Deep Dive

Sign up to receive complimentary editions of the magazine direct to your inbox, including the forthcoming ASCO & Oncology issue

Click here

Deep Dive – contact us

How to get in touch with the magazine’s editorial, commercial and design teams

Click here

Video
Share

Your name

Your e-mail

Name receiver

E-mail address receiver

Your message

Send

Share

E-mail

Facebook

Twitter

LinkedIn

Contact

Send